Resveratrol improves the anticancer effects of doxorubicin in vitro and in vivo models: A mechanistic insight

Phytomedicine

Volumn 23, Issue 3, 2016, Pages 233-242

  Rai, Girish ^a,b   Mishra, Sanjay ^a,b   Suman, Shankar ^a,b   Shukla, Yogeshwer ^a,b  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^b ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

Author keywords

Breast cancer; Cell signaling; Cytotoxicity; Doxorubicin; Ehrlich ascitic carcinoma; Resveratrol

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; BECLIN 1; CYCLOOXYGENASE 2; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; PROTEIN BAX; REACTIVE OXYGEN METABOLITE; RESVERATROL; TRANSCRIPTION FACTOR NRF2; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ASSAY; CELL INVASION; CELL MIGRATION ASSAY; CELL PROLIFERATION ASSAY; CELL VIABILITY; CHROMATIN CONDENSATION; CHRONIC INFLAMMATION; CLONOGENIC ASSAY; COLONY FORMING UNIT; COLORIMETRY; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; EHRLICH ASCITES TUMOR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SPACE; MALE; MOUSE; MOUSE MODEL; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WOUND HEALING; ANIMAL; CELL CYCLE; DRUG EFFECTS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; CARCINOMA, EHRLICH TUMOR; CELL CYCLE; CELL LINE, TUMOR; DOXORUBICIN; FEMALE; HUMANS; MALE; MICE; NF-KAPPA B; STILBENES;

EID: 84977536183     PISSN: 09447113     EISSN: 1618095X     Source Type: Journal    
DOI: 10.1016/j.phymed.2015.12.020     Document Type: Article

References (39)

1. Bianco, R., Melisi, D., Ciardiello, F., Tortora, G., Key cancer cell signal transduction pathways as therapeutic targets. Eur. J Cancer 42 (2006), 290–294.
2. Bolhassani, A., Cancer chemoprevention by natural carotenoids as an efficient strategy. Anticancer Agents Med. Chem 15:8 (2015), 1026–1031.
3. Carmichael, J., DeGraff, W.G., Gazdar, A.F., Minna, J.D., Mitchell, J.B., Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47 (1987), 936–942.
4. Chou, T.C., Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70 (2010), 440–446.
5. Colin, D.J., Limagne, E., Ragot, K., Lizard, G., Ghiringhelli, F., Solary, E., Chauffert, B., Latruffe, N., Delmas, D., The role of reactive oxygen species and subsequent DNA-damage response in the emergence of resistance towards resveratrol in colon cancer models. Cell Death Dis., 5, 2014, e1533.
6. Cook, K.L., Shajahan, A.N., Clarke, R., Autophagy and endocrine resistance in breast cancer. Expert Rev. Anticancer Ther. 11 (2011), 1283–1294.
7. Cooks, T., Pateras, Ioannis S., Tarcic, O., Solomon, H., Schetter, Aaron J., Wilder, S., Lozano, G., Pikarsky, E., Forshew, T., Rozenfeld, N., Harpaz, N., Itzkowitz, S., Harris, Curtis C., Rotter, V., Gorgoulis, Vassilis G., Oren, M., Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 23 (2013), 634–646.
8. Delmas, D., Solary, E., Latruffe, N., Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe. Curr. Med. Chem. 18 (2011), 1100–1121.
9. Delmas, D., Solary, E., Latruffe, N., Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe. Curr. Med. Chem. 18 (2014), 1100–1121.
10. Eruslanov, E., Kusmartsev, S., Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol. Biol. 594 (2010), 57–72.
11. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136 (2015), E359–E386.
12. Galustian, C., Dalgleish, A.G., The power of the web in cancer drug discovery and clinical trial design: research without a laboratory?. Cancer Inf. 9 (2010), 31–35.
13. George, J., Singh, M., Srivastava, A.K., Bhui, K., Roy, P., Chaturvedi, P.K., Shukla, Y., Resveratrol and black tea polyphenol combination synergistically suppress mouse skin tumors growth by inhibition of activated MAPKs and p53. PLoS One, 6, 2011, e23395.
14. Hoesel, B., Schmid, J.A., The complexity of NF-kappaB signaling in inflammation and cancer. Mol. Cancer, 12, 2013, 86.
15. Iwamoto, T., Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs. Biol. Pharm. Bull. 36 (2013), 715–718.
16. Kim, T.H., Shin, Y.J., Won, A.J., Lee, B.M., Choi, W.S., Jung, J.H., Chung, H.Y., Kim, H.S., Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim. Biophys. Acta. 1840 (2014), 615–625.
17. Kummar, S., Chen, H.X., Wright, J., Holbeck, S., Millin, M.D., Tomaszewski, J., Zweibel, J., Collins, J., Doroshow, J.H., Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat. Rev. Drug Discov. 9 (2010), 843–856.
18. Landskron, G., De la Fuente, M., Thuwajit, P., Thuwajit, C., Hermoso, M.A., Chronic inflammation and cytokines in the tumor microenvironment. J. Immunol. Res., 2014, 2014, 149185.
19. Lehne, G., P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr. Drug Targets 1 (2000), 85–99.
20. Li, W., Chen, L., Li, X., Jia, X., Feng, C., Zhang, L., He, W., Lv, J., He, Y., Qu, X., Zhou, Y., Shi, Y., Cancer-related marketing centrality motifs acting as pivot units in the human signaling network and mediating cross-talk between biological pathways. Mol. Biosyst. 9 (2013), 3026–3035.
21. McCarthy, N., Inflammation: Mutant p53 fans the flames. Nat. Rev. Cancer, 13, 2013, 441.
22. Osman, A.-M., Al-Harthi, S., AlArabi, O., Elshal, M., Ramadan, W., Alaama, M., Al-Kreathy, H., Damanhouri, Z., Osman, O., Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin- treated animals. Cancer Cell Int., 13, 2013, 52.
23. Pavelic, Z.P., Slocum, H.K., Rustum, Y.M., Creaven, P.J., Karakousis, C., Takita, H., Colony growth in soft agar of human melanoma, sarcoma, and lung carcinoma cells disaggregated by mechanical and enzymatic methods. Cancer Res. 40 (1980), 2160–2164.
24. Pestalozzi, B.C., Sotos, G.A., Choyke, P.L., Fisherman, J.S., Cowan, K.H., O'Shaughnessy, J.A., Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer. Cancer 71 (1993), 1797–1800.
25. Pickup, M.W., Mouw, J.K., Weaver, V.M., The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 15 (2014), 1243–1253.
26. Qadir, M.A., Kwok, B., Dragowska, W.H., To, K.H., Le, D., Bally, M.B., Gorski, S.M., Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization. Breast Cancer Res. Treat 112 (2008), 389–403.
27. Rashid, S., Ali, N., Nafees, S., Ahmad, S.T., Arjumand, W., Hasan, S.K., Sultana, S., Alleviation of doxorubicin-induced nephrotoxicity and hepatotoxicity by chrysin in Wistar rats. Toxicol. Mech. Methods 23 (2013), 337–345.
28. Ray, L., Kumar, P., Gupta, K.C., The activity against Ehrlich's ascites tumors of doxorubicin contained in self assembled, cell receptor targeted nanoparticle with simultaneous oral delivery of the green tea polyphenol epigallocatechin-3-gallate. Biomaterials 34 (2013), 3064–3076.
29. Rodriguez, L.G., Wu, X., Guan, J.L., Wound-healing assay. Methods Mol. Biol. 294 (2005), 23–29.
30. Roy, P., Kalra, N., Prasad, S., George, J., Shukla, Y., Chemopreventive potential of resveratrol in mouse skin tumors through regulation of mitochondrial and PI3K/AKT signaling pathways. Pharm. Res. 26 (2009), 211–217.
31. Shacter, E., Weitzman, S.A., 2002. Chronic inflammation and cancer. Oncology (Williston Park) 16, 217–226, 229; discussion 230–212.
32. Siddiqui, I.A., Sanna, V., Ahmad, N., Sechi, M., Mukhtar, H., Resveratrol nanoformulation for cancer prevention and therapy. Ann. N Y Acad. Sci 1348 (2015), 20–31.
33. Singal, P.K., Iliskovic, N., Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339 (1998), 900–905.
34. Thakur, J.S., Chauhan, C.G., Diwana, V.K., Chauhan, D.C., Thakur, A., Extravasational side effects of cytotoxic drugs: A preventable catastrophe. Indian J. Plast. Surg. 41 (2008), 145–150.
35. Tosetti, F., Noonan, D.M., Albini, A., Metabolic regulation and redox activity as mechanisms for angioprevention by dietary phytochemicals. Int. J. Cancer 125 (2009), 1997–2003.
36. Vinod, B.S., Maliekal, T.T., Anto, R.J., Phytochemicals as chemosensitizers: from molecular mechanism to clinical significance. Antioxid. Redox. Signal 18 (2013), 1307–1348.
37. Wang, B., Rosano, J.M., Cheheltani, R., Achary, M.P., Kiani, M.F., Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer. Expert Opin. Drug Deliv. 7 (2010), 1159–1173.
38. Wang, N., Xu, H.L., Zhao, X., Wen, X., Wang, F.T., Wang, S.Y., Fu, L.L., Liu, B., Bao, J.K., Network-based identification of novel connections among apoptotic signaling pathways in cancer. Appl. Biochem. Biotechnol. 167 (2012), 621–631.
39. Yang, X., Yu, D.D., Yan, F., Jing, Y.Y., Han, Z.P., Sun, K., Liang, L., Hou, J., Wei, L.X., The role of autophagy induced by tumor microenvironment in different cells and stages of cancer. Cell Biosci., 5, 2015, 14.